Page last updated: 2024-12-05

5-iodosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Iodosalicylic acid, also known as 5-iodosalicylic acid, is an organic compound with the formula C7H5IO3. It is a white solid that is soluble in water and ethanol. 5-Iodosalicylic acid is used as a reagent in organic synthesis, for example, in the synthesis of other iodine-containing compounds. It is also used as a disinfectant and antiseptic. The compound has been studied for its potential use in treating various medical conditions, including cancer and infections.'
```

5-iodosalicylic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8388
CHEMBL ID3278559
SCHEMBL ID129664
MeSH IDM0068159

Synonyms (38)

Synonym
brn 2090443
nsc 2789
einecs 204-313-5
119-30-2
2-hydroxy-5-iodobenzoic acid
nsc-2789
benzoic acid, 2-hydroxy-5-iodo-
salicylic acid, 5-iodo-
nsc2789
5-iodosalicylic acid
wln: qvr bq ei
inchi=1/c7h5io3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9h,(h,10,11
5-iodosalicylic acid, technical grade
I0538
AKOS000121006
A804246
5-iodo-2-hydroxybenzoic acid
BP-11486
FT-0620519
CHEMBL3278559
SCHEMBL129664
5-jod-salicylsaure
2-hydroxy-5-iodo-benzoic acid
5-iodosalicyclic acid
W-108520
AC-23694
mfcd00002458
DTXSID10152281
5-iodosalicylicacid
F0001-0305
5-iodosalycilic acid, tech.
BCP24359
BS-14523
CS-0075700
D73875
SY049057
EN300-21476
3A6XQF5B67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1302955Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption.
AID1145615Dissociation constant, pKa of the compound at pH 7.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1302958Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as TRAP-positive multinucleated cells level at 2.5 uM incubated with compound in presence of RANKL for 4 days by TRAP staining based light microscopic analysis relativ2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145616Increase in membrane potential in mollusc neurons assessed as conductance of potassium at pH 7.8 relative to salicylic acid1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145605Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1302956Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 5 uM after 24 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1302954Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 2.5 uM after 24 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]